Blueprint stumbles in GIST race, clearing path for Deciphera

Ayvakit misses Phase III primary endpoint of PFS for late-stage gastrointestinal stromal tumors

A Phase III miss for Blueprint’s Ayvakit avapritinib in third- and fourth-line GIST likely means the biotech won’t see its NDA approved in the indication, positioning Deciphera to claim a larger share of late-stage settings.

Blueprint Medicines Corp. (NASDAQ:BPMC) said Ayvakit missed the primary endpoint of progression-free survival (PFS) in the Phase III VOYAGER trial in either third-line or fourth-line patients with gastrointestinal

Read the full 625 word article

How to gain access

Continue reading with a
two-week free trial.